Which has higher earnings & valuation, JNJ or MRNA?

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.99 $26.80B $8.63 31.66 Moderna $1.94B 35.81 -$2.82B -$7.99 N/A

Is JNJ or MRNA more profitable?

Johnson & Johnson has a net margin of 21.48% compared to Moderna's net margin of -141.43%. Johnson & Johnson's return on equity of 32.42% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.48% 32.42% 13.35% Moderna -141.43% -28.30% -19.39%

Does the media favor JNJ or MRNA?

In the previous week, Moderna had 5 more articles in the media than Johnson & Johnson. MarketBeat recorded 59 mentions for Moderna and 54 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 1.09 beat Moderna's score of 0.59 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 41 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 29 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 7 Negative mention(s) 7 Very Negative mention(s) Positive

Which has stronger earnings and valuation, JNJ or NVAX?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.99 $26.80B $8.63 31.66 Novavax $1.12B 1.29 $440.30M -$1.52 N/A

Is JNJ or NVAX more profitable?

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.48% 32.42% 13.35% Novavax -59.87% -14.82% -13.35%

Does the media favor JNJ or NVAX?

In the previous week, Johnson & Johnson had 42 more articles in the media than Novavax. MarketBeat recorded 54 mentions for Johnson & Johnson and 12 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.09 beat Novavax's score of 0.33 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 41 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ABBV or JNJ?

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $64.39B 7.29 $4.23B $3.54 75.04 Johnson & Johnson $94.19B 6.99 $26.80B $8.63 31.66

Is ABBV or JNJ more profitable?

Johnson & Johnson has a net margin of 21.48% compared to AbbVie's net margin of 9.80%. Johnson & Johnson's return on equity of 32.42% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Johnson & Johnson 21.48% 32.42% 13.35%

Does the media favor ABBV or JNJ?

In the previous week, Johnson & Johnson had 5 more articles in the media than AbbVie. MarketBeat recorded 54 mentions for Johnson & Johnson and 49 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.09 beat AbbVie's score of 1.09 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Johnson & Johnson 41 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, JNJ or AZN?

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Astrazeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.99 $26.80B $8.63 31.66 Astrazeneca $58.74B 4.36 $10.23B $6.69 24.68

Does the media prefer JNJ or AZN?

In the previous week, Johnson & Johnson had 42 more articles in the media than Astrazeneca. MarketBeat recorded 54 mentions for Johnson & Johnson and 12 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.09 beat Astrazeneca's score of 0.31 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 41 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media favor JNJ or BRK.B?

In the previous week, Johnson & Johnson had 27 more articles in the media than Berkshire Hathaway. MarketBeat recorded 54 mentions for Johnson & Johnson and 27 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.09 beat Berkshire Hathaway's score of 0.51 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 41 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Berkshire Hathaway 12 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Johnson & Johnson (JNJ) Competitors

$273.19 +2.08 (+0.77%)

Closing price 08/19/2026 03:59 PM Eastern

Extended Trading

$273.64 +0.44 (+0.16%)

As of 07:21 AM Eastern

Compare

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

Should you buy Johnson & Johnson stock or one of its competitors? Johnson & Johnson's main competitors and comparable companies include Moderna (MRNA), Novavax (NVAX), AbbVie (ABBV), Astrazeneca (AZN), and Berkshire Hathaway (BRK.B). Companies are selected based on similarities in market, industry, and size.

How does Johnson & Johnson compare to Moderna?

Johnson & Johnson (NYSE:JNJ) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Johnson & Johnson has a net margin of 21.48% compared to Moderna's net margin of -141.43%. Johnson & Johnson's return on equity of 32.42% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Moderna	-141.43%	-28.30%	-19.39%

Johnson & Johnson presently has a consensus target price of $268.22, suggesting a potential downside of 1.82%. Moderna has a consensus target price of $59.69, suggesting a potential downside of 65.77%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, equities analysts plainly believe Johnson & Johnson is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.99	$26.80B	$8.63	31.66
Moderna	$1.94B	35.81	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 5 more articles in the media than Johnson & Johnson. MarketBeat recorded 59 mentions for Moderna and 54 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 1.09 beat Moderna's score of 0.59 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	41 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	29 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	7 Negative mention(s)	7 Very Negative mention(s)	Positive

Summary

Johnson & Johnson beats Moderna on 12 of the 17 factors compared between the two stocks.

How does Johnson & Johnson compare to Novavax?

Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Johnson & Johnson has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Novavax has a beta of 2.46, indicating that its share price is 146% more volatile than the broader market.

In the previous week, Johnson & Johnson had 42 more articles in the media than Novavax. MarketBeat recorded 54 mentions for Johnson & Johnson and 12 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.09 beat Novavax's score of 0.33 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	41 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Novavax	-59.87%	-14.82%	-13.35%

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.99	$26.80B	$8.63	31.66
Novavax	$1.12B	1.29	$440.30M	-$1.52	N/A

Johnson & Johnson presently has a consensus price target of $268.22, suggesting a potential downside of 1.82%. Novavax has a consensus price target of $14.00, suggesting a potential upside of 59.27%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Johnson & Johnson beats Novavax on 14 of the 17 factors compared between the two stocks.

How does Johnson & Johnson compare to AbbVie?

AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Johnson & Johnson has a net margin of 21.48% compared to AbbVie's net margin of 9.80%. Johnson & Johnson's return on equity of 32.42% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Johnson & Johnson	21.48%	32.42%	13.35%

70.2% of AbbVie shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.29	$4.23B	$3.54	75.04
Johnson & Johnson	$94.19B	6.99	$26.80B	$8.63	31.66

In the previous week, Johnson & Johnson had 5 more articles in the media than AbbVie. MarketBeat recorded 54 mentions for Johnson & Johnson and 49 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.09 beat AbbVie's score of 1.09 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Johnson & Johnson	41 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie currently has a consensus price target of $275.73, suggesting a potential upside of 3.80%. Johnson & Johnson has a consensus price target of $268.22, suggesting a potential downside of 1.82%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Johnson & Johnson has increased its dividend for 64 consecutive years.

AbbVie has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Summary

AbbVie and Johnson & Johnson tied by winning 10 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Astrazeneca?

Johnson & Johnson (NYSE:JNJ) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Astrazeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.99	$26.80B	$8.63	31.66
Astrazeneca	$58.74B	4.36	$10.23B	$6.69	24.68

Johnson & Johnson has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Johnson & Johnson presently has a consensus price target of $268.22, suggesting a potential downside of 1.82%. Astrazeneca has a consensus price target of $211.00, suggesting a potential upside of 27.81%. Given Astrazeneca's higher possible upside, analysts plainly believe Astrazeneca is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Johnson & Johnson has a net margin of 21.48% compared to Astrazeneca's net margin of 17.02%. Johnson & Johnson's return on equity of 32.42% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Astrazeneca	17.02%	31.45%	13.20%

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Johnson & Johnson had 42 more articles in the media than Astrazeneca. MarketBeat recorded 54 mentions for Johnson & Johnson and 12 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.09 beat Astrazeneca's score of 0.31 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	41 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 64 consecutive years.

Summary

Johnson & Johnson beats Astrazeneca on 17 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Berkshire Hathaway?

Johnson & Johnson (NYSE:JNJ) and Berkshire Hathaway (NYSE:BRK.B) are related large-cap companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Johnson & Johnson currently has a consensus target price of $268.22, indicating a potential downside of 1.82%. Berkshire Hathaway has a consensus target price of $542.50, indicating a potential upside of 8.54%. Given Berkshire Hathaway's higher probable upside, analysts plainly believe Berkshire Hathaway is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Berkshire Hathaway	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Berkshire Hathaway has a net margin of 22.30% compared to Johnson & Johnson's net margin of 21.48%. Johnson & Johnson's return on equity of 32.42% beat Berkshire Hathaway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Berkshire Hathaway	22.30%	6.62%	3.87%

In the previous week, Johnson & Johnson had 27 more articles in the media than Berkshire Hathaway. MarketBeat recorded 54 mentions for Johnson & Johnson and 27 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.09 beat Berkshire Hathaway's score of 0.51 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	41 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Berkshire Hathaway	12 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Berkshire Hathaway has higher revenue and earnings than Johnson & Johnson. Berkshire Hathaway is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.99	$26.80B	$8.63	31.66
Berkshire Hathaway	$438.31B	2.44	$66.97B	$39.77	12.57

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 39.3% of Berkshire Hathaway shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 6.1% of Berkshire Hathaway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Johnson & Johnson has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Berkshire Hathaway has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Johnson & Johnson beats Berkshire Hathaway on 10 of the 17 factors compared between the two stocks.

Get Johnson & Johnson News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JNJ vs. The Competition

Export

Metric	Johnson & Johnson	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$653.35B	$12.20B	$7.17B	$24.19B
Dividend Yield	1.98%	2.66%	2.55%	3.73%
P/E Ratio	31.66	779.77	268.95	30.14
Price / Sales	6.99	763.30	620.03	19.93
Price / Cash	19.20	96.52	78.23	31.97
Price / Book	7.75	12.14	13.24	6.84
Net Income	$26.80B	$2.81B	$3.47B	$1.07B
7 Day Performance	4.05%	1.17%	2.25%	-0.57%
1 Month Performance	9.79%	2.61%	5.33%	2.97%
1 Year Performance	52.97%	8.76%	29.22%	18.26%

Johnson & Johnson Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JNJ Johnson & Johnson	4.703 of 5 stars	$273.19 +0.8%	$268.22 -1.8%	+53.7%	$653.35B	$94.19B	31.66	138,200	Positive News Insider Trade Options Volume
MRNA Moderna	1.7026 of 5 stars	$59.74 -0.1%	$42.13 -29.5%	+524.8%	$23.81B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume Gap Up
NVAX Novavax	1.7851 of 5 stars	$7.80 -1.1%	$13.00 +66.6%	-7.7%	$1.28B	$1.12B	N/A	1,990	Trending News Options Volume
ABBV AbbVie	4.8111 of 5 stars	$248.23 +0.1%	$275.70 +11.1%	+29.0%	$438.56B	$64.39B	70.12	57,000	Positive News Analyst Forecast Insider Trade
AZN Astrazeneca	4.8817 of 5 stars	$159.48 -1.5%	$211.00 +32.3%	+3.8%	$247.40B	$58.74B	23.84	96,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JNJ) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Summary

How does Johnson & Johnson compare to Novavax?

Summary

How does Johnson & Johnson compare to AbbVie?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Which has more risk & volatility, JNJ or MRNA?

Do insiders and institutionals hold more shares of JNJ or MRNA?

Is JNJ or MRNA more profitable?

Do analysts rate JNJ or MRNA?

Which has higher earnings & valuation, JNJ or MRNA?

Does the media favor JNJ or MRNA?

Summary

How does Johnson & Johnson compare to Novavax?

Which has more risk and volatility, JNJ or NVAX?

Does the media favor JNJ or NVAX?

Is JNJ or NVAX more profitable?

Do institutionals and insiders hold more shares of JNJ or NVAX?

Which has stronger earnings and valuation, JNJ or NVAX?

Do analysts rate JNJ or NVAX?

Summary

How does Johnson & Johnson compare to AbbVie?

Is ABBV or JNJ more profitable?

Do institutionals & insiders hold more shares of ABBV or JNJ?

Which has higher valuation & earnings, ABBV or JNJ?

Does the media favor ABBV or JNJ?

Do analysts rate ABBV or JNJ?

Is ABBV or JNJ a better dividend stock?

Which has more risk & volatility, ABBV or JNJ?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Which has preferable valuation and earnings, JNJ or AZN?

Which has more volatility and risk, JNJ or AZN?

Do analysts prefer JNJ or AZN?

Is JNJ or AZN more profitable?

Do institutionals & insiders believe in JNJ or AZN?

Does the media prefer JNJ or AZN?

Is JNJ or AZN a better dividend stock?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Do analysts rate JNJ or BRK.B?

Is JNJ or BRK.B more profitable?

Does the media favor JNJ or BRK.B?

Which has higher valuation & earnings, JNJ or BRK.B?

Do insiders and institutionals have more ownership in JNJ or BRK.B?

Which has more risk and volatility, JNJ or BRK.B?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools